Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013

Am J Surg. 2017 Aug;214(2):323-328. doi: 10.1016/j.amjsurg.2016.08.008. Epub 2016 Sep 2.

Abstract

Background: Recent incidence, treatment patterns, and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported.

Methods: State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and stage I breast cancer excluding MIBC (stage 1BC).

Results: From 2000 to 2013, 1,706, 193, and 4,514 women were diagnosed with DCIS, MIBC, and stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (P = .041). MIBC was more frequently human epidermal growth factor receptor 2 positive than stage 1BC (39.7% vs 9.6%, P < .001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, P = .014) or stage 1BC (40.9% vs 33.8%, P = .119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and stage 1BC.

Conclusions: Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.

Keywords: Breast neoplasms; Cancer incidence; Mastectomy; Microinvasive tumor; SEER program.

MeSH terms

  • Breast Neoplasms* / chemistry
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / therapy
  • Carcinoma, Intraductal, Noninfiltrating* / chemistry
  • Carcinoma, Intraductal, Noninfiltrating* / epidemiology
  • Carcinoma, Intraductal, Noninfiltrating* / pathology
  • Carcinoma, Intraductal, Noninfiltrating* / therapy
  • Female
  • Humans
  • Incidence
  • Iowa
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Receptor, ErbB-2 / analysis
  • SEER Program

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2